Biomea Fusion (Biomea Fusion) FCF Yield % : -22.48 (As of May. 05, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Biomea Fusion FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Biomea Fusion's Trailing 12-Month Free Cash Flow is $-99.96 Mil, and Market Cap is $444.71 Mil. Therefore, Biomea Fusion's FCF Yield % for today is -22.48%.

The historical rank and industry rank for Biomea Fusion's FCF Yield % or its related term are showing as below:

BMEA' s FCF Yield % Range Over the Past 10 Years
Min: -33.77 Med: 0 Max: 0
Current: -22.48

BMEA's FCF Yield % is ranked worse than
60.46% of 1553 companies
in the Biotechnology industry
Industry Median: -14.39 vs BMEA: -22.48

Biomea Fusion's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Biomea Fusion FCF Yield % Historical Data

The historical data trend for Biomea Fusion's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomea Fusion FCF Yield % Chart

Biomea Fusion Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-17.80

-25.46

-19.19

Biomea Fusion Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial												-33.57	-11.72	-13.41	-19.49	-17.55

Competitive Comparison of Biomea Fusion's FCF Yield %

For the Biotechnology subindustry, Biomea Fusion's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomea Fusion's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's FCF Yield % falls into.

Biomea Fusion FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Biomea Fusion's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-99.962	/	520.783032
	=	-19.19%

Biomea Fusion's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-22.845	*	4	/	520.783032
	=	-17.55%

Biomea Fusion FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Biomea Fusion FCF Yield % Related Terms

Thank you for viewing the detailed overview of Biomea Fusion's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomea Fusion (Biomea Fusion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomea Fusion Inc (NAS:BMEA) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Middlefield Road, 4th Floor, Redwood City, CA, USA, 94063

Website

https://www.biomeafusion.com

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Executives

Juan Pablo Frias	officer: Chief Medical Officer	900 MIDDLEFIELD ROAD, 4TH FLOOR, C/O BIOMEA FUSION, INC., REDWOOD CITY CA 94063
A2a Pharmaceuticals, Inc.	10 percent owner	59 5TH AVE, NEW YORK NY 10003
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director, 10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hitchcock Michael J.m.	director	C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Franco Valle	officer: Chief Financial Officer	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Elizabeth Faust	director	C/O BIOMEA FUSION, INC., 900 MIDDLEFIELD RD., 4TH FL, REDWOOD CITY CA 94063
Sumita Ray	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Sotirios Stergiopoulos	director	C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Rainer M Erdtmann	director, 10 percent owner, officer: President and COO	1073 ARLINGTON BLVD., EL CERRITO CA 94530
Thomas Andrew Butler	director, 10 percent owner, officer: CEO	726 MAIN STREET, REDWOOD CITY CA 94065
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Biomea Health, Llc	10 percent owner	726 MAIN STREET, REDWOOD CITY CA 94063